Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

• DOI: 10.1097/tp.0b013e31820c10eb
• Publication Date: 2011-03-05T13:28:38Z
• Authors: Yves Vanrenterghem; Barbara Bresnahan; Josep Campistol; Antoine Durrbach; Josep Grinyó; Hans-Hellmut Neum...; Philippe Lang; Christian P. Larsen; Eduardo Mancilla-...; José Medina Pestana; Alan Block; Tao Duan; Alan Glicklich; Sheila Gujrathi; Flavio Vincenti
• Keywords: Belatacept

Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly calcineurin inhibitors. Belatacept, selective co-stimulation blocker, may provide better cardiovascular/metabolic risk profile than current immunosuppressants.Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT BENEFIT-EXT) belatacept-based regimens in recipients were assessed at month 12. Each study belatacept more intensive (MI) less (LI) versus cyclosporine A (CsA). These secondary included changes blood pressure, serum lipids, incidence new-onset diabetes after (NODAT).A total 1209 patients randomized transplanted across studies. Mean systolic pressure was 6 to 9 mm Hg lower mean diastolic 3 4 MI LI groups CsA (P ≤ 0.002) both Non-HDL cholesterol (P<0.01 or vs. each study). Serum triglycerides (P<0.02 NODAT occurred often prespecified pooled analysis (P<0.05 CsA).At 12, associated cardiovascular profiles, lipids CsA. The overall will continue over 3-year trials.